{"id":"typhoid-vi-vaccine","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Injection site pain or erythema"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Myalgia"},{"rate":"1-3","effect":"Fever"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108822","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified Vi polysaccharide from the outer capsule of Salmonella typhi, which is recognized by B cells to generate protective antibodies and by T cells to establish cellular immunity. This immune response prevents infection when exposed to wild-type typhoid bacteria. The Vi antigen is a key virulence factor that protects the bacteria from complement-mediated killing, making it an effective immunogenic target.","oneSentence":"The Typhoid Vi vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi by presenting the bacterial Vi polysaccharide capsular antigen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:54.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of typhoid fever caused by Salmonella typhi in travelers and at-risk populations"}]},"trialDetails":[{"nctId":"NCT05500482","phase":"PHASE4","title":"Vellore Typhoid Vaccine Impact Trial","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2023-05-01","conditions":"Typhoid Fever","enrollment":72400},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06630884","phase":"PHASE1","title":"Inflammatory Challenge and Fear","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-28","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":288},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT05745987","phase":"PHASE4","title":"Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT","status":"RECRUITING","sponsor":"McMaster University","startDate":"2024-09-17","conditions":"Monkeypox","enrollment":3000},{"nctId":"NCT04741828","phase":"PHASE2, PHASE3","title":"Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2021-05-03","conditions":"Vaccine","enrollment":188},{"nctId":"NCT03299426","phase":"PHASE3","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-21","conditions":"Typhoid","enrollment":30000},{"nctId":"NCT03614533","phase":"PHASE2","title":"Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-12-03","conditions":"Typhoid","enrollment":251},{"nctId":"NCT06757283","phase":"PHASE3","title":"ZyVac-TCV Bangladesh Study","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Typhoid Vaccination, Typhoid, Typhoid Fever","enrollment":4000},{"nctId":"NCT05613205","phase":"PHASE1","title":"Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-11-28","conditions":"Typhoid Fever","enrollment":97},{"nctId":"NCT05475379","phase":"PHASE1, PHASE2","title":"Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-07-01","conditions":"Typhoid","enrollment":630},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT02429531","phase":"PHASE4","title":"Polysaccharide Antibody Response Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-10","conditions":"Specific Polysaccharide Antibody Deficiency","enrollment":200},{"nctId":"NCT03968211","phase":"PHASE1","title":"Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2019-07-01","conditions":"Immune Deficiency","enrollment":37},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT06116669","phase":"NA","title":"Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women","status":"UNKNOWN","sponsor":"Swiss Federal Institute of Technology","startDate":"2023-11-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06027801","phase":"NA","title":"Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-09-06","conditions":"Iron Deficiency Anemia","enrollment":150},{"nctId":"NCT05771779","phase":"PHASE3","title":"Co-administration Study of OCV, TCV and MR","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-14","conditions":"Typhoid, Cholera, Measles","enrollment":2117},{"nctId":"NCT05119426","phase":"PHASE4","title":"Effectiveness of a Typhoid Conjugate Vaccine in DRC","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2022-02-11","conditions":"Typhoid Fever","enrollment":48000},{"nctId":"NCT05346302","phase":"EARLY_PHASE1","title":"Persistent Readiness Through Early Prediction Immunization Study","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2022-02-08","conditions":"Inflammatory Response","enrollment":249},{"nctId":"NCT02715635","phase":"PHASE1","title":"Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2016-04","conditions":"Cardiovascular Diseases","enrollment":78},{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT04051268","phase":"PHASE3","title":"Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-03-02","conditions":"Safety Issues, Immunogenicity","enrollment":3071},{"nctId":"NCT03889158","phase":"PHASE4","title":"Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2019-03-25","conditions":"Aging, Inflammation","enrollment":35},{"nctId":"NCT04830371","phase":"PHASE2, PHASE3","title":"Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-09-07","conditions":"Typhoid Fever","enrollment":444},{"nctId":"NCT03554213","phase":"","title":"Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-07-02","conditions":"Enteric Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":17292},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285},{"nctId":"NCT03048929","phase":"EARLY_PHASE1","title":"Inflammation and Threat Sensitivity in PTSD","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-01","conditions":"Posttraumatic Stress Disorder","enrollment":30},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03460405","phase":"PHASE2","title":"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2018-07-16","conditions":"Safety Issues, Immunogenicity","enrollment":600},{"nctId":"NCT03956524","phase":"PHASE1","title":"Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2019-03-16","conditions":"Typhoid Fever","enrollment":75},{"nctId":"NCT03294564","phase":"EARLY_PHASE1","title":"Cognitive, Emotional, and Neural Responses to Acute Inflammation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-01-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT03926455","phase":"PHASE1","title":"Safety and Immunogenicity of Typhax, a Typhoid Vaccine","status":"COMPLETED","sponsor":"Matrivax Research and Development Corporation","startDate":"2016-03-28","conditions":"Typhoid Fever","enrollment":45},{"nctId":"NCT02628054","phase":"NA","title":"Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-02","conditions":"Typhoid Vaccine on Sleep","enrollment":16},{"nctId":"NCT03109600","phase":"PHASE1","title":"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2017-04-18","conditions":"Safety Issues","enrollment":100},{"nctId":"NCT02286544","phase":"PHASE1","title":"Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2014-10","conditions":"Myocardial Infarction, Inflammation, Acute Coronary Syndrome (ACS)","enrollment":36},{"nctId":"NCT00386789","phase":"","title":"Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-10-05","conditions":"Typhoid Fever","enrollment":""},{"nctId":"NCT00277147","phase":"PHASE1","title":"Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-01-09","conditions":"Typhoid Fever","enrollment":25},{"nctId":"NCT01582321","phase":"EARLY_PHASE1","title":"Investigation of the Influence of Gender on Cardiovascular Function","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2012-03","conditions":"Cardiovascular Function","enrollment":56},{"nctId":"NCT00197249","phase":"PHASE3","title":"Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Hepatitis A","enrollment":1034},{"nctId":"NCT02175420","phase":"NA","title":"Role of BCG as Booster Vaccination","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-07","conditions":"BCG Vaccination","enrollment":30},{"nctId":"NCT01608815","phase":"PHASE3","title":"Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-05","conditions":"Salmonella Infections, Typhoid Fever, Bacterial Infections","enrollment":200},{"nctId":"NCT00326443","phase":"PHASE1","title":"CVD 909 Vi Prime Boost Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"Typhoid Fever","enrollment":21},{"nctId":"NCT01533285","phase":"EARLY_PHASE1","title":"Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2012-05","conditions":"Major Depressive Disorder","enrollment":40},{"nctId":"NCT01438996","phase":"PHASE2","title":"Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-10","conditions":"Typhoid Fever","enrollment":51},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT01193907","phase":"PHASE2","title":"Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Typhoid Fever","enrollment":88},{"nctId":"NCT01123941","phase":"PHASE1","title":"Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-05","conditions":"Typhoid Fever","enrollment":50},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301},{"nctId":"NCT00125047","phase":"PHASE4","title":"Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":27231},{"nctId":"NCT00125008","phase":"PHASE4","title":"Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2003-05","conditions":"Typhoid, Paratyphoid Fever","enrollment":37673},{"nctId":"NCT00131820","phase":"PHASE4","title":"Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-12","conditions":"Typhoid, Paratyphoid Fever","enrollment":100742},{"nctId":"NCT00131833","phase":"PHASE4","title":"Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":96468}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Typherix"],"phase":"marketed","status":"active","brandName":"Typhoid Vi vaccine","genericName":"Typhoid Vi vaccine","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Typhoid Vi vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi by presenting the bacterial Vi polysaccharide capsular antigen. Used for Prevention of typhoid fever caused by Salmonella typhi in travelers and at-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}